WA
IBRX icon

Waverly Advisors’s ImmunityBio IBRX Stock Holding History

Waverly Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
27,255
-303
-1% -$2.29K ﹤0.01% 1540
2026
Q1 		$211K Sell
27,558
-17,331
-39% -$119K ﹤0.01% 1467
2025
Q4 		$88.9K Sell
44,889
-9
-0% -$20 ﹤0.01% 1432
2025
Q3 		$110K Buy
44,898
+9,890
+28% +$25.5K ﹤0.01% 1252
2025
Q2 		$92.4K Buy
35,008
+15,084
+76% +$40.6K ﹤0.01% 1166
2025
Q1 		$60K Buy
19,924
+5,162
+35% +$15.6K ﹤0.01% 1100
2024
Q4 		$37.8K Buy
+14,762
New +$61.5K ﹤0.01% 978

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Waverly Advisors's IBRX Position: Q2 2026 in Review

Waverly Advisors reduced its ImmunityBio (IBRX) stake by 1.1% in Q2 2026, selling an estimated $2.29K and leaving 27,255 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Waverly Advisors first reported a position in IBRX in Q4 2024 and has held it in 7 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Waverly Advisors held 27,255 shares of ImmunityBio worth $239K as of Q2 2026.
  • Waverly Advisors sold 303 ImmunityBio shares in Q2 2026, an estimated $2.29K.
  • ImmunityBio made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1540 holding.
  • Waverly Advisors first reported a position in ImmunityBio in Q4 2024 and has held it in 7 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.